Compare Alibaba Group (BABA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs Merck & Co., Inc. — how do they compare? Alibaba Group trades at $124.44 (market cap $308.93B), while Merck & Co., Inc. trades at $132.44 (market cap $321.77B). The key difference: Alibaba Group and Merck & Co., Inc. are close in size by market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| BABA | MRK | |
|---|---|---|
Market Cap | $308.93B | $321.77B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $131.84 |
52-Week Low | $94.83 | $77.60 |
Enterprise Value | $303.72B | $368.53B |
Dividend Yield | 0.82% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BABA trades at $132.32, up 3.04% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong 2025 results with $996.35B revenue and $130.11B net income, though recent quarterly EPS misses raise concerns. Analyst consensus remains strongly bullish with an $195.00 price target, but multiple class action lawsuits filed in August 2026 create significant legal overhang.
BABA presents a mixed investment case with strong fundamentals and Wall Street support offset by legal risks and earnings volatility. The stock trades at reasonable valuations (P/E 19.61, P/S 2.03) with solid profitability metrics, but investors must weigh the substantial legal challenges against the company's operational strength and growth trajectory.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
